SALES FORECAST: The Swiss pharma giant's third-quarter sales are forecast at 14.89 billion Swiss francs ($17.22 billion), according to a consensus of 11 analysts' estimates compiled by Visible Alpha.

Roche Holding AG will add manufacturing capacity in China to serve the country’s growing market, making it the latest ...

Shares of Roche Holding AG (OTCQX:RHHBY) pulled back this month after the disappointing obesity pipeline updates where both the injectable and oral candidates showed poor tolerability. The company ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG (RHHVF – Research ...

Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical ...

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer Jazz Pharmaceuticals released Phase 3 trial ...

ROCHE Holding will add manufacturing capacity in China to serve the country’s growing market, making it the latest ...

Scholar Rock Holding Corp (SRRK) showcases promising developments in its clinical pipeline, with significant progress in SMA and obesity treatments. GWI research commissioned by Roche (SIX ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Roche Holding AG (RHHBY) current and estimated P/E ratio data provided by Seeking Alpha.